Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label and Single-arm Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT07368270 is registered in ClinicalTrials.gov with Jiangsu Topcel-KH Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07368270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07368270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label and Single-arm Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
January 31, 2026
Completion date
January 31, 2029
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma